- Home
- MTD vs ROIV Comparison
MTD vs ROIV Comparison
Compare MTD & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MTD | ROIV |
|---|---|---|
| Founded | 1991 | 2014 |
| Country | Switzerland | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.6B | 25.1B |
| IPO Year | 1997 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MTD | ROIV |
|---|---|---|
| Price | $1,325.52 | $41.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 9 |
| Target Price | ★ $1,444.17 | $28.94 |
| AVG Volume (30 Days) | 155.7K | ★ 6.8M |
| Earning Date | 05-07-2026 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.88 | N/A |
| EPS | ★ 19.87 | N/A |
| Revenue | ★ $4,026,399,000.00 | $8,260,000.00 |
| Revenue This Year | $6.07 | N/A |
| Revenue Next Year | $4.75 | $744.61 |
| P/E Ratio | $67.70 | ★ N/A |
| Revenue Growth | ★ 3.98 | N/A |
| 52 Week Low | $1,023.05 | $13.40 |
| 52 Week High | $1,525.17 | $37.97 |
Technical Indicators
Market Signals| Indicator | MTD | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 36.03 | 72.41 |
| Support Level | $1,230.16 | $27.15 |
| Resistance Level | $1,356.41 | N/A |
| Average True Range (ATR) | 33.94 | 1.35 |
| MACD | -12.37 | 0.14 |
| Stochastic Oscillator | 7.33 | 88.42 |
Price Performance
Historical ComparisonAbout MTD Mettler-Toledo International Inc.
Mettler-Toledo supplies weighing and precision instruments to customers in the life sciences (around 55% of sales), industrial (around 40%), and food retail (around 5%) industries. Its products include laboratory and retail scales, pipettes, pH meters, thermal analysis equipment, titrators, metal detectors, and X-ray analyzers. Mettler leads the market for weighing instrumentation and controls more than 50% of the market for lab balances. The business is geographically diversified, with the Americas accounting for about 37% of sales, Europe about 27%, China about 16% and the rest of the world about 20%.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.